Gates Foundation Strategic Investment Fund Logo
Share this page:

Fierce Biotech: Genentech forms $1B discovery collaboration with soil-prospector Lodo Therapeutics

By Conor Hale

May 9, 2018

Genentech signed a broad, open-ended drug discovery collaboration with Lodo Therapeutics that could be worth nearly $1 billion, focused on deriving unique, natural products from the microbial DNA found in soil.

The drugmaker plans to use Lodo’s metagenome-prospecting platform to identify novel small molecules with therapeutic potential against a wide range of diseases and targets. While the upfront payment was not disclosed, Lodo is eligible for development milestone bonuses totaling up to $969 million, as well as tiered royalties based on future sales.


Read the full press release here.